Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904741 | 0.91 | TP53 (0.56) | TP53POLBENPP2THRBNLRP3 | |
| SCHEMBL4909240 | 0.79 | TP53 (0.50) | TP53POLBENPP2THRBNLRP3 | |
| SCHEMBL4913319 | 0.79 | TP53 (0.49) | TP53POLBENPP2THRBNLRP3 | |
| SCHEMBL7498257 | 0.78 | TP53 (0.66) | TP53POLBTHRBNLRP3MAPT | |
| SCHEMBL4913329 | 0.77 | TP53 (0.49) | TP53POLBENPP2THRBNLRP3 | |
| SCHEMBL4913324 | 0.76 | TP53 (0.47) | TP53POLBENPP2THRBNLRP3 | |
| SCHEMBL4903864 | 0.76 | BRD4 (0.42) | TP53POLBMAPT | |
| SCHEMBL4784069 | 0.74 | CYP2C19 (0.60) | POLBMAPTSMN1; SMN2LMNA | |
| SCHEMBL17966857 | 0.71 | ENPP2 (1.00) | TP53POLBENPP2HPGDGAA | |
| SCHEMBL30100351 | 0.71 | ENPP2 (1.00) | TP53POLBENPP2HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | TP53 1937/4885POLB 3/4885ENPP2 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.